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Abstract
Glioblastoma multiforme (GBM), a high-grade, malignant brain tumor of
astrocyte origin, invades normal brain tissue and most often results in death ofthe patient
within a year of diagnosis. In order to invade the surrounding tissue and thereby
metastasize, these tumor cells must migrate through the extracellular matrix. The
pmpose ofthis research project is to investigate the family of matrix metalloproteinases
responsible for extracellular degradation. Specifically, this investigation looks at MMP-2
activation via MT1-MMP and the possible importance ofphosphorylation of the tyrosine
residue on the cytoplasmic tail ofMTl-MMP. U87 wild type glioma cells as well as T98
p53 mutant glioma cells were treated with transforming growth factor beta (TGF-P).
P reliminary results indicate a lesser concentration ofM Tl-M M P and a greater
concentration of phosphorylated tyrosine (P-Tyr) in the treated U87 cells. Similar
experiments with T98 cells indicate a lesser concentration ofM Tl-M M P in the treated
samples and no effect on the phosphorylation of tyrosine. Results with TGF-P-treated
T98 cells imply that TGF-P does not upregulate MTl-M M P production. U87 cells were
also treated with epidermal growth factor (EGF). Results indicate a greater concentration
ofM Tl-M M P as well as a greater concentration ofphosphorylated tyrosine in the EGF
treated conditions. Zymography results shows no effect ofEGF treatment on MMP-2
production. While TGF-P has not been found to upregulate M Tl-M M P production in
either U87 or T98 cells, results do indicate that EGF upregulates M Tl-M M P as well as
phosphorylation of the tyrosine residue in U87 cells.
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Introduction
Gliomas originate from glial cells in the brain and are among many tumors which
arise from an imbalance in cell proliferation and cell death. Frequently referred to as
astrocytomas, gliomas often originate from astrocytes. In the United States alone, nearly
twenty-five thousand new cases of gliomas surface annually, making gliomas the most
common primary tumor of the brain (Furuta et al., 2004). Gliomas can occur in the
cerebellum, causing such symptoms as headache, vomiting and unsteadiness in walking.
Gliomas also occur in the posterior cerebral hemisphere, often causing seizures
(Zimmerman et al., 1956). Gliomas, or astrocytomas, are divided into two main types:
low-grade and high-grade. In contrast to localized, low-grade gliomas which are
characterized by slow growth, high-grade tumors are characterized by aggressive, rapid
growth and require intensive therapy. The two most common high-grade gliomas are
Anaplastic Astrocytoma (AA-grade III) and Glioblastorna Multiforme (GBM-grade IV).
As a high-grade, malignant brain tumor, GBM has an incredible ability to invade the
surrounding nonnal brain tissue. GBM often causes infiltrated cells to escape detection
and avoid surgical resection, eventually leading to tumor recurrence in another part of the
brain. Although patients diagnosed with high-grade astrocytomas commonly receive
both radiation and chemotherapy, prognosis is poor. Fewer than 5% of patients with
GBM treated with aggressive therapy for a year survive for five years (Furuta et al.
2004). Furthermore, most patients die within a year of diagnosis (Furuta et al. 2004).
One major objective of research involving gliomas is to understand how these tumor cells
migrate in order to develop anticancer therapy.
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In order for cancer cells to metastasize, they must migrate through the
extracellular matrix (ECM). Extracellular matrices contribute to tissue architecture, with
extracellular matrices components regulating and influencing such processes as cell
growth, differentiation and adhesion. The extracellular matrix in the brain includes such
components as tenascin, neurocan, and hyaluronan. Matrix metalloproteinases (MMPs)
have been implicated in the proteolytic cascades resulting in ECM degradation, and thus
are an important point of study in tumor cell migration. Research has shown that MMPs
are upregulated in almost all types of human cancer, and that their expression is often
indicative of poor survival due to an increase in the invasive and metastatic potential of
the tumor (Egeblad and Werb, 2002).
+

The MMP family is made up of nearly thirty enzymes which are all Zn2



dependent endopeptidases (Chang and Werb, 2001). These enzymes are broken up into
eight structural classes: simple hemopexin domain, gelatin-binding minimal domain,
furin-activated and secreted, transmembrane, GPI-linked, vitronectin-like insert and Type
II transmembrane. MMPs are initially secreted in an inactive form as proenzymes, and
are later activated to create the mature MMP enzyme. MMPs play a large role in the
regulation of tumor microenvironments and regulate ce11 behaviors pertinent to cancer
cell biology such as growth, differentiation, apoptosis, invasion and migration (Egeblad
and Werb, 2002). One such noteworthy MMP enzyme, MMP-2, has been positively
correlated with glioma cell invasion (Ubm et al., 1997). MMP-2 is synthesized by tumor
stromal cells such as inflammatory cells, fibroblasts myofibroblasts and endothelial cells.
Like other MMPs, MMP-2 is initially secreted in its proenzyme form referred to as
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proMMP-2 with a length of68kDa. This proMMP-2 molecule is activated by a cleavage
complex into its active MMP-2 form at 62kDa.
One specific group ofMMPs referred to as MT-MMPs is unique in that each MT
MMP contains a short cytoplasmic tail and a hydrophobic transmembrane domain at the
C-terrninus which dictates localization to the cell surface (Gingras et al., 2000). One
such MT-MMP family member is a 63kDa, membrane-anchored enzyme called MTl
MMP. MTl-MMP makes up part ofthe cleavage complex responsible for activation of
MMP-2. Specific research on MTl-MMP has indicated that its cytoplasmic domain
plays an important role in cell invasion by controlling the cell's targeting and degradation
processes (Lehti et al., 1999). It has also been shown that there are three possible
phosphorylation sites on the cytoplasmic tail ofMTl -MMP: Serine577, Tyrosine573 and
Threonine567 (Lehti et al., 2000). This project investigates the possibility that regulation
ofMTl-MMP may be the result ofphosphorylation oftyrosine on its cytoplasmic tail.
Additionally, considerable evidence has demonstrated that tissue inhjbitor of
metalloproteinases (TIMPs) are also involved in promoting tumor activity. For example,
a positive correlation between tissue levels ofTIMP-1 and more invasive stages ofcancer
has been found in colon cancer cells (Blavier et al., 1999). Another TIMP molecule,
TIMP-2, serves as an adaptor molecule regulating proMMP-2 activation. TIMP-2 ha
also been correlated with an increase in tyrosine phosphorylation ofproteins as it
stimulates adenylate cyclase and cyclic AMP-dependent activation ofprotein kinase A
(Blavier et al., 1999). TIMP-2 is part ofa cleavage complex formed between one MTl 
MMP enzyme and one TIMP-2 molecule which can be cleaved by an adjacent MTl-
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MMP molecule, ultimately resulting in a trimolecular complex. It is this membrane
bound, trimolecular complex which is responsible for MMP-2 activation outside the cell.
Upregulat:ion of proMMP-2 production occurs through various signal transduction
pathways activated by exogenous growth factors. Growth factors bind to transmembrane
cell receptors, subsequently initiating phosphorylation cascades inside the cell. Both
epidermal growth factor (EGF) and transforming growth factor beta (TGF-P) are among
the exogenous growth factors known to be expressed by tumors (Rooprai et al., 2000).
Transforming growth factor beta (TGF-P) plays a vital role in tumorigenesis,
acting as a key determinant of carcinoma cell behavior (Derynck et al., 2001). The TGF
p Ras signaling pathway is complex in that it is both a tumor suppressor pathway and a
promoter pathway of tumor progression and invasion. In regards to tumor progression,
TGF-Pl has been known to stimulate extracellular matrix protein synthesis and the
chemoattraction of fibroblasts, resulting in a micro-environment that promotes tumor
growth (Derynck et al., 200 I). In addition to promoting tumor growth, TGF-PI catalyzes
migration and invasiveness of gliomas (Merzak et al., 1994). Coinciding research has
also shown an inverse correlation between TGF-Pl expression in human gliomas and
survival rate (Merzak et al. 1994). In regards to MMP-2, TGF-P has been shown to
stimulate the transcription of proMMP-2 (Overall et al., 1989).
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Figure 1: Transforming growth factor-beta (TGF-P) signaling pathway.
TGF-P binds to TGF-P receptors on the glioma cell surface, activating a Ras
signal transduction pathway which stimulate tran cription of proMMP-2. The
cleavage complex formed by two MT l -MMP molecules and one TIMP-2
molecule then converts proMMP-2 into active MMP-2.
Epidermal growth factor (EGF) also regulates many ignal-dependent pathways in
tumors, and specifically stimulates tyrosine kinase ca cades. When treated with EGF,
tumor pheroids from the human glioma cell line GaMG show increased growth cell
shedding and tumor ceJI migration (Lund-Johan en et al., 1992). One study howed an
antagonistic relationship between sequential radiation and admini tration of 1 3-bis 2chloroethyl)-1-nitrosourea (BCNU) chemotherapy in three primary human glioblastoma
cell lines (Chakravarti et al., 2002). These cell lines demon trated strong expres ion of
EGF, and in the presence of an EGF inhibitor cro s-re i tance between radiation and
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chemotherapy was abrogated (Chakravarti et al., 2002). Thus, the epidermal growth
factor receptor pathway may provide resistance to chemotherapy and radiation in
gliomas.
proMMP-2

active MMP-2

EGF

EGF receptors

Figure 2: Epidermal growth factor (EGF) signaling pathway. EGF binds to
EGF receptors on the U87MG gliorna cell surface, activating a signal
transduction pathway which stimulates tyrosine kinase cascades.
Phosphorylation ofthe tyrosine residue on the cytoplasmic tail ofMTl-MMP
may affect the MTI-MMP-dependent activation ofMMP-2.

The relationship between the tyrosine phosphorylation ofMTl-MMP's
cytoplasmic tail and activity ofMMP-2 is studied in this project using the U87MG p53
wild type and T98G p53 mutant cell lines derived from human glioblastoma multiforme.
U87MG cells are homozygous for the p53 genotype and express p53 proteins with wild
8

type transactivation activities (Van Meir et al., 1994). Wild type p53 promotes cell cycle
arrest. The World Health Organization defines high-grade gliomas as the result ofserial
accumulations ofgenetic alterations which inactivate tumor suppressor genes such as p53
(Furuta et al., 2004). One such glioma cell line, T98G, is homozygous for the p53
genotype and is mutant at codon 237 (an alteration from ATG to ATA). This point
mutation causes the replacement ofthe normal amino acid methionine with isoleucine
(Van Meir et al., 1994). The MMP-2 gene contains a p53 binding site at its promoter
(Bian and Sun, 1997).
In this project, both U87MG and T98G cells are treated with TGF-P and
subsequently analyzed for MMP-2 levels as well as concentration ofMTl -MMP and
corresponding phosphorylation oftyrosine. Additionally, the experiment is repeated with
EGF using only U87MG cells. It is expected that treatment with TGF-P or EGF wiU
upregulate MTl -MMP and P-Tyr in both U87MG and T98G cell lines. Furthermore, it is
expected that an increase in the concentration ofMTI-MMP as well as its
phosphorylation will coincide with an increase in MMP-2 activity in 087 cells. Because
T98G cells are mutant for p53, it is expected that upregulation ofMTI-MMP and P-Tyr
will not produce a drastic increase in proMMP-2 or active MMP-2 levels.

9

Materials and Methods
U87 and T98 mutant cell lines of human glioblastoma multiforme were used to
investigate the relationship between activity of MMP-2 and the concentration of MTl
MMP as well as phosphorylation of tyrosine via several procedures: passing cell ,
treating cells, immunoprecipitation, gel electrophoresis, Bradford Assay, Western Blot
and chemiluminescence.
Passing Cells
Initially, one T25 flask was inoculated with 300,000 cells and then split in order
to obtain the maximum number of viable cells. To split the cells phosphate buffered
saline (PBS: 8%NaCI, 1.15% Na2 HPO4, 0.2% KCl, 0.2%KH2PO4), Dulbecco's Modified
Eagle Medium (DMEM: 500mL DMEM, 5mL NEAA, 5mL PenStrep, 0.5ml
Gentamycin SQ4) with fetal bovine serum (FBS: 50mL) and DMEM without FBS were
warmed in a 37° C water bath. Frozen I OX Trypsin EDTA was heated in the water bath
until thawed and then inverted a few times and kept on ice. Trypsin for washing the cells
was made with 1.25mL I OX Trypsin EDTA and 3.75ml DMEM without FBS for a T25
flask (3.75mL IOX Trypsin EDTA and l l .25m.L DMEM without FB for a T75 flask).
Media was removed from the cells and cells were washed with 6mL PB for a
T25 flask (18.0mL for a T75). PBS was transferred to a waste beaker and celJs were then
washed with 4m.L of prepared Trypsin for a T25 flask (12.0mL for a T75). Cell were
incubated for at least 3 minutes and then looked at under a microscope to ensure cells
were floating. The flask was bit sharply on the side when necessary to dislodge the cells.
9mL of DMEM with FBS were added to the flask to stop the action of the Trypsin in a
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25. flask (27.0mL for a T75). The contents of the flask were transferred to a 50mL
onical tube and centrifuged for ten minutes at 1,300 rpm at room temperature. The
upematant was removed and 1.0mL DMEM with FBS was added to resuspend the pellet
or the pellet was resuspended in l mL ofDMEM with FBS five times, culminating in a
otal volume of 5mL for the resuspended pellet). A cell count was performed using a
emacytometer and the appropriate number of cells was aliquoted into T25 flasks
ontaining 5mL DMEM with FBS for treatment or into a T25 or T75 flask (the latter
containing l 5mL media) for maintenance of a stock.
reating Cells
When cells reached 90-95% confluency, they were treat�d with TGF-P (US
iological T8250- 15A). DMEM without FBS and PBS were warmed in a 37° C water
ath. Media was removed from the cells of two T25 flasks, and cells were rinsed with
mL PBS. The PBS was removed from the flask and then 5mL DMEM without FBS was
dded to each flask. To the treatment flask, IOµl of a 5ng/µl sample of TGB-P ( l µI
GF-P freshly diluted in 9µ1 Bovine Serum Albumin-PBS solution) was added. Both
asks were incubated for forty-eight hours.
mmunoprecipitation

Lyse cells with PfS
Nutate supernatant with washed agarose
xg
Nutate supernatant with MT1-MMP antibody overnight
xg

Nutate lysate with washed agarose
xg

Wash pellets
xg
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Cells were immunoprecipitated after forty-eight hours of incubation following
treatment. 6mL of protease inhibitor solution (PIS per mL: 833µ1 PBS, 147µ1 50mM
n-octyl glucopyranoside [Sigma 0-9882], 10µ1 1µg/mL aprotinin [Sigma A-6279], 5µ1
lmM phenylmethylsulfonyl fluoride [PMSF; Sigma P-7626], 2µ1 1µg/mL Pepstatin A
[Sigma P-53 18], 1µ1 l mM CaCh, 1µ1 l mM MgCh, 1µ1 lµg/mL leupeptin) was made up
for the treated and untreated T25 flasks. All conditioned media was removed from each
T25 flask and frozen for later use in the zymogram. The cells were rinsed with 6mL of
warm PBS three times. After the third rinse the PBS was drained for two to four minutes
(with the flasks standing on end) and all additional liquid was pipetted off. 2mL of PIS
was pipetted into each flask to lyse the cells, and the flasks were placed on ice gently
rocking for one hour (ensuring the flasks were flat so that the PIS completely covered the
cells). After an hour, the liquid was pulled out of the +TGF-f3 flask and put into two
microcentrifuge tubes (approx. 1 mL per tube). The same was done for the -TGF-f3 flask.
Tubes were spun down for fifteen minutes at 14,000 rpm at 4 ° C. While the tubes were
spinning, washed agarose was prepared. 150µ1 of agarose (Calbiochem JP06) from the
stock tube was put into a new microfuge tube. 1,500µ1 of PIS was added to the tuoe and
the tube was lightly vortexed. The tube was then spun down for one minute, and the
supernatant was removed and discarded. The agarose pellet was resuspended in 150µ1 of
PIS.
For irrununoprecipitation procedure A:
Two samples per treatment were simultaneously prepared in order to run
duplicate gels after immunoprecipitation.

12

When the lysates stopped spinning, the supematants from each condition were
removed and the preclear pellet was frozen. 30µ1 of washed agarose was combined with
each sample tube (2 separate tubes for +TGF-13 with approximately l mL of sample in
each; 2 separate tubes for -TGF-13 with approximately 1 mL of sample in each). All four
tubes were left to nutate at 4 °C for two hours. After two hours, tubes were spun down at
14,000 rpm for fifteen minutes at 4 °C. An aliquot of the supernatant was saved on ice for
a sessment of protein concentration using a Bradford Assay. The remaining precleared
lysate (the supernatant) was saved for the gel (one tube per treatment) and stored at 4 °C.
Two tubes with 50µ1 of supernatant and 3µI of MTl-MMP antibody ( 1 µg/µI; Chern icon
International, AB815) per treatment condition were nutated overnight at 4 °C. A
Bradford Assay was performed at this point.
For immunoprecipitation procedure B:
One larger sample per treatment was prepared by immunoprecipitation to run one
gel to be blotted, stripped and reblotted.
When the lysates stopped spinning, the supernatants from the two treated tubes
were combined in one sterile, round-bottom tube and the supematants from the two
untreated tubes were combined in one sterile round-bottom tube· preclear pellets were
frozen. 60µ1 of washed agarose was combined with the supernatant, and both tubes were
placed in the nutator at 4 °C for two hours. The contents of the round-bottom tube were
transferred to microcentrifuge tubes to be spun down at 14,000 rpm for fifteen minutes at
4°C. An aliquot of the supernatant was saved on ice for assessment of protein
concentration using a Bradford Assay. The remaining precleared lysate (the supernatant)
was saved for the gel (one tube per treatment) and stored at 4 °C. 100µ1 of supernatant
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with 6µ1 of MTl -MMP antibody (lµg/µl) per treatment condition were nutated overnight
at 4°C. A Bradford Assay was performed at this point.
For the second day of immunoprecipitation procedure A, 30µ1 of washed agarose
was added to each tube which had nutated overnight, and tubes then nutated at room
temperature for two hours. For the second day of immunoprecipitation procedure B, 60µ1
of washed agarose was added to each tube which had nutated overnight, and tubes then
nutated at room temperature for two hours.
For both procedures, all tubes were then centrifuged at 10,000 rpm for fifteen
minutes at 4° C. The resulting supernatant was the no MTl condition saved at -20° C. 24
ml of wash solution were prepared (5ml stock solution [0.5M NaCl and 50mM Tris-HCI
in superwater, pH 7.4] + 2.5µ1 Tween-20 [Sigma P-7949]). The pellets were washed six
times with 1ml wash solution per wash. They were centrifuged at 10,000 rpm for five
minutes at 4° C between each wash.
Gel Electrophoresis

Samples were then prepared to run on a gel. Initially, duplicate gels were run but

modifications in procedure Jed to one gel being run with stripping in between blotting.
Further modifications led to loading 10µl of sample instead of 20µ1 of sample (and thus
reducing sample buffer and reducing agent by one half) due to bleeding of gel lanes.
Later on, only IP-MTl samples were loaded (freezing preclear and no MTl samples for
later use). In the later gels, for the no MTl and preclear lanes that were loaded, 10µl
sample, 3µ1 4x sample buffer (Invitrogen NP0007) and 1.3µ1 reducing agent (Invitrogen
NP0004) were combined. For the standard See Blue plus 2, I 0µl tandard (Invitrogen
LC5925), 3µ1 4x sample buffer and 1.3µ1 reducing agent were combined. The earlier
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method of preparing the gel used double these amounts (20µ1 sample, 10µ1 standard
+ 10µ1 superwater). For the washed pellet (MTI condition), 20µ1 (immunoprecipitation
procedure A) or 40µ1 (immunoprecipitation procedure B) of 2x sample buffer was added
and the solution was incubated in a heating block (submerged in water) at 90°C for five
minutes. The tube was then centrifuged for two minutes and 10µ1 of the sample was
prepared by adding 3µ1 of 2X sample buffer and 1.3µ1 of reducing agent to run on a gel.
Remaining MTl supernatant was frozen at -20° C. All gel samples, including the
standard, were then incubated in a heating block (submerged in water) for ten minutes at

10 ° c.

For the 4-12% Bis-Tris gel (Invitrogen NP032 l ), 1,000mL of running buffer

(lnvitrogen NP0002) for the outside chamber was made up using 50mL running buffer
and 950mL superwater. 200mL of this solution was aliquoted out for the inner chamber
of the gel with 500µ1 NuPage Antioxidant (Invitrogen NP0005) added.
The gel was run at 200 volts for 35 minutes with lanes typically loaded in the
following manner when preclear and no MTl samples were run in addition to MTl
samples:

II

preclear

I

-TGF-B
no MTI

I

II

IP-MTl

II

preclear

+TGF-B
no MTl

I

I

TP-MT1

When only MTl samples were used, samples were typically loaded in the
following manner:
[

std

-TGF-B
,
IP-MTl

I

I

+TG F-B
IP-MTI

I
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I

I

I

After 35 minutes, the gel was transferred to nitrocellulose at 30 volts for one hour
in IX NuPage transfer buffer (Invitrogen NP0006-l ). The top left comer of the
nitrocellulose was cut for orientation purposes, and the nitrocellulose was left to dry
overnight.
Bradford Assay

For both immunoprecipitation procedures A and B, a Bradford Assay was

performed on the precleared lysate aliquots to identify protein concentrations. For
protein concentration assessment, test tubes were typically prepared as indicated below,
with two sample test tubes made up for each treatment condition:
Blank: 3mL Bradford Coomasie Protein Reagent (Pierce 1856209), 100µ1
superwater
Sample: 3mL Bradford Coomasie Protein Reagent, 75µ1 sample, 25µ1 superwater
Blank and samples were inverted to mix and then incubated for ten minutes at room
temperature. The spectrophotometer was set at 595nm and zeroed with the blank.
bsorbance values were recorded, and an average absorbance value for each treatment
condition was calculated.
Western Blot

For each immunoprecipitation procedure, both MTI-MMP and phosphotyrosine

(P-Tyr) blots were performed.
To begin the Western blot, IOX tris-buffered saline (TBS: 1.54 NaCl and 0.I0M
Tris-HCI pH 7.4) was made. Then it was diluted 1:10 for use in the Western blot. IOmL
IX TBS+ 0.3g milk powder were thoroughly mixed per each nitrocellulose paper. The
nitrocellulose was rehydrated in superwater and rolled protein-side-in into a bottle. The
TBS/milk powder solution was poured into the bottle and the bottle with the
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nitrocellulose blocked for sixty minutes. The solution was removed and replaced with
'IOmL Ix Tl3S and rotated for ten minutes. During this time, lOOmL TBS-T (99.8mL Ix
TBS + 0.2g tnilk powder+ 200µ1 Tween-20) was made up per blot. The TBS was
poured off the nitrocellulose and replaced with 7.5mL TBS-T along with 1.5µ1 rabbit
anti-MTI-MMP primary antibody ( 1mg/ml; Chemicon International, AB815) for MTl
MMP blots or 1µl phosphotyrosine primary antibody (7mg/ml; Chemicon International

AB 1599) fot P-Tyr blots. The nitrocellulose was rotated for sixty minutes at room

temperature. The TBS-T-antibody mix was poured off and replaced with IOmL TBS-T

rotating for 10 minutes. The TBS-T wash step was repeated twice more. 7.5mL TBS-T
and 1.5µ1 goat anti-rabbit secondary antibody (200µg in 0.5ml; Santa Cruz, SC-2004)
were added and the nitrocellulose was rotated for 60 minutes. The TBS-T-antibody mix
was poured

off and the blot was washed with l OmL TBS-T for five minutes.

This step

was repeated three more times and was immediately followed by chemiluminescence.
Chemiluminescence
To ptepare for chemiluminescence, first 7mL of 1:1 mixture of enhanced
chemiluminescence (ECL [Amersham Biosciences RPN2209]: 3.5mL reagent 1+ 3.5mL
reagent 2) rehydrated the nitrocellulose blot for approximately one minute. ECL reagents
were drained from the nitroceUulose onto a paper towel, and the nitrocellulose was
wrapped in saran wrap. The nitrocellulose was taped down in an x-ray tray, and a piece
of film was cut to match the nitrocellulose. The tray was closed and the film was
exposed for one minute (exposure time was adjusted as needed). After exposure, the film
was placed into the developer for one minute. Then the film was transferred to the stop
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bath for apptoximately three minutes with slight agitation. Finally, the film was
transferred to the fixer for at least thirty seconds of constant agitation.
Stripping a Blot
The blot was rehydrated in superwater and then stripped for 20 minutes using
I0mL Pierce's Restore Western Blot Stripping Buffer at 37° C. The blot was then washed
with I 0mL of IX TBS for ten minutes at room temperature and then washed again with
I0mL of IX TBS for five minutes. Blot was stored at 4 ° C in TBS-T until another
Western was repeated.
Altei-hatively, the blot was rehydrated in superwater and stripped for fifteen
minutes at room temperature using 20rnL of IX Antibody Stripping Solution (Chernicon
0513). Stripping was then followed by two five minute washes with blocking solution
(same as blocking solution used in the Western). Blot was stored at 4 ° C in TBS-T until
another Western was repeated.
Zymography
Zyitiography was also performed using the conditioned media saved at the
beginning of the immunoprecipitation. To start, 15µ1 of the conditioned media was
mixed with 15µ1 2X Tris-glycine SDS sample buffer (Invitrogen LC2676) and a 1: 100
dilution ofGelatinase Zymography Standard (Chemicon CC073) was prepared using the
2X Tris-glycine SDS sample buffer. All samples were incubated for ten minutes at room
temperature. While the mixture was incubating, the gel apparatus was set up using a 10%
zymogram gel (Inyitrogen EC6175BOX) in IX DS running buffer (Invitrogen LC26755). After loading the gel with the conditioned media and 8µ1 of the diluted standard, the
gel was ruh at 120 volts for 90 minutes at room temperature. 1Ox renaturing buffer
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..
(Invitrogeri LC2670) was used to wash the gel at room temperature with agitation for
thirty minutes. After thirty minutes the gel was put in IX developing buffer (Invitrogen
LC2671) at 37°C overnight. The gel was then stained using 0.5% Coomassie Blue Stain
(25% isoptopanol, 10% glacial acetic acid, superwater, Brilliant Blue R [Sigma B-0149])
for at least one hour and fifteen minutes with agitation and then removed and destained
with agitation for three hours with destaining solution (10% isopropanol, 10% HOAc,
80% superwater).
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U87 or T98 cells

Incubate without growth factor

I

Incubate with TGF-Beta or EGF

48 Hours

Conditioned Media

Cell Lysate

Zymogram for MMP-2
activity

Immunoprecipitate with MTl
MMP antibody

Western Blot for MTl-MMP
and Phosphotyrosine
Figure 3: Flow chart detailing methods. Sequence of treatment, imrnunoprecipitation
and western blot anal sis of U87 and T98 cells.

Results
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Treatment with Transforming Growth Factor Beta (TGF-fJ)

U87 and T98 cells were treated with I Ong/ml ofTGF-�. Following treatment,
conditioned media was saved for zymography to assess MMP-2 activity. Cells were
lysed using a protease inhibitor solution and the lysate was then incubated with agarose to
clear it ofrtonspecifically-binding proteins. The subsequent precleared lysate was u ed
for immunoprecipitation with MTl -MMP primary antibody.
After treating U87 cells with TGF-�, western blot analysis oftwo
immunoprecipitation experiments shows le s MTl-MMP in the treated condition as
compared to the untreated (Figure 4). Although a Bradford As ay indicates that the
untreated sample had almost double the protein concentration ofthe treated sample,
densitometry data indicates at least a three-fold difference in band strength, confirming
that the untreated sample has a greater concentration ofMTl-MMP (Table 1 and Figure
4). The percent change oftreated to untreated sample is 46.9%, demonstrating more than
a doubling ofMTl-MMP in the untreated sample as compared to the treated.
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densitome

treated
386,976.82
0.025
0.25
1,547,908
46.9

untreated
1 386,000.00
0.042
0.42
3,300,000

Figure 4: Western blot for MTl-MMP in 087 cells.
Immunoprecipitation followed by Western blot analysis
using an MTl -MMP primary antibody reveaJs a greater
concentration of MTl-MMP in the untreated sample.
Western blot analysis for MTl-MMP on one other U87 immunoprecipitation did not
confirm these results (Table I). Furthermore, protein concentrations for the experiment
contradicting the above resuJts (Figure 4) were the highest of all irnmunoprecipitations
performed in this research project (Table 1). Two U87 immunoprecipitations produced
inconclusive results due to errors in the loading of the gel or lack of data on protein
concentrations (Table I).
Western blot analysis for phosphorylated tyrosine on several immunoprecipitation
experiments using TGF-P-treated U87 cells is inconclusive (Table 1). Three out of four
immunoprecipitations demonstrated a greater concentration of P-Tyr in the treated
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condition with the average percent change at 223.2%. However, one
imrnunoprecipitation produced contradictory results with a percent change of 69.3%
(Table 1).
For T98 cells treated with TGF-P, the general trend across immunoprecipitation
experiments indicates less MTl-MMP protein in the treated condition as well as less
phosphorylated tyrosine (Table 1; Figures 5 and 6). In one representative
immunoprecipitation, although protein concentration in the untreated sample is less than
the treated sample by 0.073µg/µl, densitometry of the bands sJightly under the 62kDa
mar k in the MTl sample lanes indicates that the untreated sample still has a ignificantly
greater band intensity corresponding to MTI-MMP (Figure 5). The percent change of
treated to untreated sample is 59.5%, demonstrating close to a doubling of MTl-MMP in
the untreated sample as compared to the treated.
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untreated
204,344.13
0.250
2.50
81,738

treated
157,214.92
0.323
3.23
48,673
59.5

Figure 5: Western blot for MTl-MMP in T98 cells.
Immunoprecipitation followed by Western blot analysis
using an MTl-MMP primary antibody reveals a greater
concentration ofMTl-MMP in the untreated sample.

Three other immunoprecipitation experiments confinn this data, with an average
percent change among the four experiments of 61.0% (Table 1). However, one T98
immunoprecipitation showed contradictory results with a greater concentration ofMTl
MMP in the treated sample (Table I).
A Western for phosphorylated tyrosine using the same nitrocellulose as shown
above (Figure 5) indicates less protein in the treated MTl sample lane (Figure 6).
Densitometry indicates that the untreated MT l sample has almost double the band
strength per microgram ofprotein loaded as compared to the treated sample with a 57.6%
change (Figure 6). However data from three other immunoprecipitation experiments
does not confirm this data, showing an average percent change of 103.1% (Table 1).
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densitometry
concentration (uir/µl)
amount loaded (ug)
densitometry/ug
percent change

untreated
312,100.00
0.250
2.50
124,840

-

treated
232,235.29
0.323
3.23
71,899
57.6

Figure 6: Western blot for P-Tyr in T98 cells.
Following Western blot for MTl-MMP as shown in
Figure 5, the nitrocellulose was stripped and rebJotted
for phosphotyrosine. Blot shows greater band strength
at 62kDa in the untreated sample.
After treating with TGF-P and then completing five immunoprecipitation
experiments on T98 cells (samples from two experiments were rerun on a gel) and four
immunoprecipitation experiments on U87 cells (samples from one experiment were rerun
on a gel), results were inconsistent (Table 1 ). In order to ensure equal amounts of protein
across treatments two immunoprecipitation samples were blotted for actin. Results
indicate that for these two immunoprecipitation experiments, equal protein in the
untreated and treated lanes was loaded (Figure 7).
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Figure 7: 087 and T98 cell line immunoprecipitation samples
blotted for actin. In order to ensure that the same amount of
protein was present in each sample so that comparative results were
accurate, three immunoprecipitation samples were loaded on a gel
and blotted for actin. Results indicate equal band strength across
treatments within the T98 cell line, thus ensuring that differences in
band strength observed for these experiments when blotted for MTl
or P-Tyr are not due to a difference in overall protein concentration
but rather to a difference in levels ofMTl or P-Tyr.

Zymography on treated U87 and T98 conditioned media arnples was also inconclusive,
and therefore the data was not included.
Treatment with Epidermal Growth Factor (EGF)
U87 cells were treated with 20ng and 80ng ofEGF. Following treatment
conditioned media was saved for zymograpby to assess MMP-2 activit y. Cells were
lysed using a protease inhibitor solution and the Iysate was then incubated with agaro e to
clear it ofnonspecifically-binding proteins. The subsequent precleared ly ate wa u ed
for immunoprecipitation with MT1-MMP primary antibody.
Subsequent Western blot analy is with MTl-MMP antibody reveals an increase in
concentration in the treated Janes (Figure 8A). Although development ofthis blot i
uneven, densitometry analysis subtracts the background and indicates that treatment with
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EGF increases MTl -MMP concentration with 80ng EGF resulting in a 228.1% change a
compared to the untreated condition. Western blot analy is of the ame
irnmunoprecipitation using a phosphotyro ine antibody al o reveal an increase in
concentration in the treated lanes (Figure 8B).

Std

MT1-MMP

Phosphotyrosine

-EGF +20ng +80ng

Std

62 kDa-

-EGF +20ng +80ng

62 kDa-

A

densitometry
concentration
(µQ/µJ)
amount
loaded (µg)
densitometryI
U!!

percent
change

-EGF
64,927.96

MTl-MMP
+20ng
+80ng
70,672.07 118,465.15

-EGF
39,589.27

P-Tvr
+20ng
43,955.24

+80ng
52,776.06

0.150

0.160

0.120

0.150

0.160

0.120

3.00

3.20

2.40

3.00

3.20

2.40

21,642

22,085

49,360

13,196

13,736

21,990

-

102.1

228.1

-

104.1

166.6

Figure 8: Treatment ofU87 cells with epidermal growth factor. Comparison of MT1MMP in untreated cells (-EGF) and cells treated with 20ng EGF (+20ng) and 80ng EGF
(+80ng). Western blot (A) monitors the presence of MTl-MMP using an MTI-MMP
primary antibody. Western blot (B) monitors the presence of phosphorylated MTl-MMP at
the tyrosine phosphorylation site using a phosphotyrosine primary antibody. An anti-rabbit
secondary antibody was used for both blots. Each Western blot was preceded by an
immunoprecipitation that yielded an MTI sample for each condition. ee Blue Plus 2
standard was used on both gels, but the MT1-MMP antibody does not recognize the
proteins in the standard. Both blots show an increase in protein concentration in the
treated lanes.
Zymography on conditioned media from EGF-treated U87 cells howed no effect
on levels of MMP-2 (Figure 9). Furthermore re ults indicate a slight conversion of
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proMMP-2 (68kDa) into active MMP-2(62kDa). The faint upper bands at 92kDa
probably correspond to secreted MMP-9.

Std

(-) +20 +80

(-) +20 +80

M

p
A
Figure 9: Zymogram of conditioned media from U87 cells treated with epidermal
growth factor. Comparison ofMMP-2 activity in untreated cells(-), cells treated with
20ng EGF (+20), and cells treated with 80ng EGF (+80). The standard has thick bands
due to MMP-9 (M) and MMP-2(A). The two sets of bands are representative of two
different sets ofexperiments. The zymography results show the inactive pro form(P) of
the enzyme at 68kDa and a faint band representing the active form(A) which migrates
ahead ofthe pro form at 62kDa.
Discussion

Data collected from immunoprecipitations ofboth U87 and T98 cells when
treated with transforming growth factor beta is inconsistent. A generalized conclusion
based on two U87 immunoprecipitations shows less MT l -MMP in the treated sample.
This data fails to validate data produced last year (Cox, 2004). Additionally, data from
these two experiments may not be reliable because absorbance values taken on the lysate
are below 0.1 and thus protein concentrations were low. Data for P-Tyr using U87
immunoprecipitation samples is also inconclusive, although the majority of experiments
indicate a greater concentration ofphosphorylated tyrosine in the treated condition. This
majority data includes the immunoprecipitation with the highest protein concentration.
However, this conclusion also fails to validate data produced last year (Cox, 2004).
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Furthermore, immunoprecipitation samples producing the most reliable MTI-MMP data
showed less P-Tyr in the treated condition which contradicts three other
immunoprecipitations that demonstrated greater P-Tyr concentration in the treated
condition. It should be noted that although the tyrosine on the cytoplasmic tail ofMTl
MMP is known to be phosphorylated, this research project does not include data that
indicates that it is this tyrosine residue on the cytoplasmic tail which is phosphorylated.
Contradictory results for both MTl-MMP and P-Tyr in U87 cells treated with
transforming growth factor beta may be due to inadequate protein concentrations. For
each immunoprecipitation done with U87 cells, at least one sample if not both the
untreated and treated samples had an absorbance 595nm value ofless than 0.1 (Table 1 ).
The general trend for T98 immunoprecipitations according to densitometry shows
greater band strength in the untreated lanes for MTl-MMP and no effect on the
phosphorylation oftyrosine with a percent change of103.1 % when comparing treated
samples to untreated samples. These findings imply that treatment with TGF-B in T98
cells does not facilitate the production ofMTl-MMP.
The T98 p53 mutant cell line has an inactivated p53 tumor suppres or gene. The
tumor suppressor protein, p53, acts as a transcription factor for the MMP-2 gene.
Without this tumor suppressor protein transcription ofMMP-2 may be hindered.
Because zymography data was inconclusive for both cell lines, a generalization about the
connection between the phosphorylated state ofMTl-MMP and its activation cannot be
made, nor about MT l-MMP's effect on the production ofMMP-2. However, one might
expect that TGF-B would have a similar effect on MTl-MMP production and
phosphorylation in both cell lines with treatment producing a change in MMP-2 levels in
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U87 cells and little change in MMP-2 levels in T98 cells as transcription ofMMP-2 is
hampered.
There were a number of potential reasons why theTGF-P immunoprecipitation
results were inconclusive. Halfway through the semester, newTGF-� was ordered and
aliquoted to ensure that the growth factor was still functional. Additionally, the
procedure was modified from immunoprecipitation procedure A to immunoprecipitation
procedure B as stated in the methods to ensure that immunoprecipitation samples were
being treated identically. Furthermore, when possible, duplicate gels of
immunoprecipitation samples were run in order to eliminate the loss of protein due to
stripping in between blotting forMTI-MMP and for phosphorylated tyrosine. Especially
for U87, protein concentrations across immunoprecipitation experiments were too low.
An effort was made to allow the cells to become even more confluent before treating but
this did not seem to improve the protein concentration. Originally, cells were treated
with 1 Ong/ml TGF-� based on a previous concentration curve (Lewis, 2003). However,
when results indicated little difference in band strength across treatments, another
concentration curve was performed to verify the optimal concentration for treatment.
This concentration curve treated U87 cells with 10ng/ml, 50ng/ml and IO0ng/ml ofTGF
p and indicates that treatment with 100ng/ml as opposed to 10ng/ml may be most optimal
for clear results. Additional immunoprecipitation experiments using l 00ng/mlTGF-P for
treatment of cells would be appropriate.
Finally, zymography results on U87 and T98 cells treated with transforming
growth factor beta are inconclusive. Future experiments should ensure that a zymogram
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is run on fresh conditioned media as zymograpby on refrozen samples was found to be
ineffective due to the degradation ofprotein from thawing and refreezing.
Treatment ofU87 cells with epidermal growth factor correlated with an increase
in MTl-MMP levels as well as an increase in phosphotyrosine levels. Percent change
for MTI-MMP and P-Tyr were 102.1% and 104.1% respectively for 20ng EGF and
228.1% and 166.1% respectively for 80ng EGF (Figure 8). This data indicates more than
a doubling ofMTI-MMP with treatment of80ng EGF and an almost 50% increase for P
Tyr. The effect ofEFG on MTl-MMP at 80ng appears to be greater than its effect on P
Tyr. These conclusions are supported by duplicate experiments. The increase in MTI
MMP implies that EGF may play a role in the activation ofMTJ-MMP. However since
EGF treatment did not affect the amount ofproMMP-2, the amount and phosphorylation
state ofMTl-MMP have no observable effect on MMP-2 levels. The effect ofthe
phosphorylation state ofMTl-MMP on the activation ofMMP-2 cannot be deduced
because only a small portion ofproMMP-2 in the conditioned media is converted to the
active form irrespective oftreatment with EGF. The active MMP-2 form migrates at
62kDa, a slightly smaller size than the pro-form at 68kDa which is cleaved by the MTl
MMP/TIMP-2 complex during activation. Although these results confirm one
experiment (Lewis, 2003), they do not confirm the majority ofpast research which
indicates that production and secretion ofMMP-2 increases with increasing EGF
concentrations (Rooprai et al, 2000; Uhm et al., 1997; Weed, 2004). Further re earch
investigating the effects ofepidermal growth factor might elucidate EGF's role in MMP2 production. Since past research indicates that TIMP-2 indirectly stimulates tyrosine
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phosphorylation, it would be interesting to investigate TIMP-2 levels in EGF-treated U87
cells.
Results from this research project, although inconclusive for treatment with
transforming growth factor beta, do indicate that EGF upregulates MT 1-MMP production
as well as P-Tyr. Further research, including appropriate zymography results, must be
performed before conclusions can be made regarding MTl -MMP's effect on the
activation of MMP-2.
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MT1MMP

Densitometry (Net intensity)/µg

Treatment
MT1MMP

P-TYR

P-TYR

MT1-MMP

P-Tvr

Percent Change

Line

-TGF

+TGF

TGF

U87

less

more

less

more

101,839

U87

gel

gel

less

more

-

-

U87

more

less

less

more

3,300,000

1,547,908

645,893

1,255,176

46.90%

194.30%

U87

more

less

less

372,108

225,723

318,296

220,446

60.70%

-

-

-

69.30%

U87

-

more

T98

more

-

38.80%

-

T98

-

65.80%

-

-

79.80%

-

59.50%

57.60%

Cell

+TGF

-TGF

+TGF

-TGF

+TGF

MT1MMP

P-Tvr

233,126

290,029

504,076

228.90%

173.80%

365,361

1,101,760

-

301.60%

-

less

gel

gel

149,259

57,845

more

less

gel

gel

302,629

199,240

T98

more

less

gel

gel

98,488

78,561

--

T98

more

less

more

less

81,738

48,673

124,840

71,899

T98

gel

gel

even

even

-

49,228

48,104

-

T98

gel

gel

even

even

-

-

146,330

163,306

-

111.60%

T98

less

more

even

even

174,360

302,695

111,077

111,012

173.60%

99.90%

-

-

-

-

97.70%

Table 1: lmmunoprecipitation data from U87 and T98 samples treated with TGF-Jl. Values in
parentheses indicate an absorbance 595nm value of less than 0.1. "Gel" indicates that results were
inconclusive due to procedural problems. "Even' indicates that results were inconclusive because
there was no significant difference in band strength.
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